NVAX

#2240
Novavax Inc
8.39 USD
+3.45%
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
8.39
8.39
Jahresspanne
5.80
11.97
Tagesänderung
+3.45%
Monatliche Änderung
-19.09%
6 month change
-6.15%
Jahresänderung
+31.30%
Vorheriger Schlusskurs
8.11
Eröffnung
8.39
Bid
Ask
Tief
8.39
High
8.39
Volumen
93
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Dividenden
Vierteljährlich Jährlich
Gewinn- und Verlustrechnung Bilanz Cashflow
Wert 202020212022202320242025 TTM

Novavax Inc

Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria. Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine.

Nachrichten